Michael Lanthier

669 total citations
12 papers, 448 citations indexed

About

Michael Lanthier is a scholar working on Economics and Econometrics, Immunology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michael Lanthier has authored 12 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 4 papers in Immunology and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michael Lanthier's work include Pharmaceutical Economics and Policy (10 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Michael Lanthier is often cited by papers focused on Pharmaceutical Economics and Policy (10 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Michael Lanthier collaborates with scholars based in United States, Thailand and Israel. Michael Lanthier's co-authors include Kathleen L. Miller, Clark Nardinelli, Hala Shamsuddin, Leonard Sacks, Rachel E. Sherman, Janet Woodcock, Rachel E. Behrman, Edward Cox, John Farley and Nicole M. Mahoney and has published in prestigious journals such as JAMA, Nature Reviews Drug Discovery and Clinical Infectious Diseases.

In The Last Decade

Michael Lanthier

12 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Lanthier United States	9	213	82	75	73	63	12	448
Amanda Wilson United Kingdom	9	194 0.9×	199 2.4×	170 2.3×	38 0.5×	98 1.6×	33	805
Neil McAuslane United Kingdom	15	447 2.1×	24 0.3×	54 0.7×	59 0.8×	76 1.2×	59	578
Esther F. Schmid United Kingdom	12	67 0.3×	99 1.2×	61 0.8×	25 0.3×	55 0.9×	19	385
Gigi Hirsch United States	7	135 0.6×	42 0.5×	25 0.3×	19 0.3×	37 0.6×	15	268
Marisa Papaluca United Kingdom	11	48 0.2×	101 1.2×	43 0.6×	33 0.5×	25 0.4×	17	412
Ulrik Schulze Switzerland	7	94 0.4×	118 1.4×	50 0.7×	10 0.1×	51 0.8×	15	350
Alexander C. Egilman United States	10	164 0.8×	19 0.2×	24 0.3×	33 0.5×	41 0.7×	22	290
Entela Xoxi Italy	10	222 1.0×	68 0.8×	34 0.5×	43 0.6×	23 0.4×	20	370
Joseph P. Griffin United States	6	94 0.4×	90 1.1×	13 0.2×	32 0.4×	20 0.3×	15	352
Sandro Gsteiger Switzerland	13	136 0.6×	44 0.5×	48 0.6×	42 0.6×	36 0.6×	26	654

Countries citing papers authored by Michael Lanthier

Since Specialization

Citations

This map shows the geographic impact of Michael Lanthier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lanthier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lanthier more than expected).

Fields of papers citing papers by Michael Lanthier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lanthier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lanthier. The network helps show where Michael Lanthier may publish in the future.

Co-authorship network of co-authors of Michael Lanthier

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Lanthier. A scholar is included among the top collaborators of Michael Lanthier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Lanthier. Michael Lanthier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Miller, Kathleen L. & Michael Lanthier. (2024). Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals. Health Affairs. 43(1). 18–26. 5 indexed citations

Mahoney, Nicole M., et al.. (2020). An Analysis of Antibacterial Drug Development Trends in the United States, 1980–2019. Clinical Infectious Diseases. 73(11). e4444–e4450. 37 indexed citations

Lanthier, Michael, et al.. (2019). An Analysis of Follow‐On Development in New Drug Classes, January 1986–June 2018. Clinical Pharmacology & Therapeutics. 106(5). 1125–1132. 8 indexed citations

Miller, Kathleen L. & Michael Lanthier. (2018). Investigating the landscape of US orphan product approvals. Orphanet Journal of Rare Diseases. 13(1). 183–183. 30 indexed citations

Miller, Kathleen L., et al.. (2017). Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals. Drug Safety. 40(6). 497–503. 30 indexed citations

Miller, Kathleen L. & Michael Lanthier. (2016). Trends In Orphan New Molecular Entities, 1983–2014: Half Were First In Class, And Rare Cancers Were The Most Frequent Target. Health Affairs. 35(3). 464–470. 26 indexed citations

Miller, Kathleen L. & Michael Lanthier. (2015). Innovation in biologic new molecular entities: 1986–2014. Nature Reviews Drug Discovery. 14(2). 83–83. 29 indexed citations

Sacks, Leonard, et al.. (2014). Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012. JAMA. 311(4). 378–378. 153 indexed citations

Lanthier, Michael, Kathleen L. Miller, Clark Nardinelli, & Janet Woodcock. (2013). An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011. Health Affairs. 32(8). 1433–1439. 91 indexed citations

10.

Lanthier, Michael, Rachel E. Behrman, & Clark Nardinelli. (2008). Economic issues with follow-on protein products. Nature Reviews Drug Discovery. 7(9). 733–737. 36 indexed citations

11.

Lanthier, Michael. (2003). War Widows and the Expansion of the French Welfare State. The Journal of the Abraham Lincoln Association. 31. 1 indexed citations

12.

Rosenberg, Amy S., et al.. (2003). Riposte: FDA response to ‘Yin, yang and the biopharmaceutical industry’. Journal of Commercial Biotechnology. 10(1). 36–39. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact